August 8, 2011
FierceBiotech By John Carroll Will FDA officials raise the regulatory bar on biosimilars so high they can’t be competitive in the U.S.? Longtime researcher and Parexel consultant Dr. Saurabh Aggarwal seems to think there’s a very high risk of that. In an interview with Scientific American blogger Khadijah Britton, Aggarwal says that the FDA’s latest […]
August 5, 2011
PharmaTimes By Lynne Taylor To feel comfortable with generic biologics (biosimilars), US payers are likely to require more clinical information than what might be accepted by the Food and Drug Administration (FDA) for approvals, a new report suggests. For example, FDA approval of biosimilar versions of monoclonal antibodies (MAbs) for oncology indications will not allay […]
August 5, 2011
PharmaTimes By Lynne Taylor To feel comfortable with generic biologics (biosimilars), US payers are likely to require more clinical information than what might be accepted by the Food and Drug Administration (FDA) for approvals, a new report suggests. For example, FDA approval of biosimilar versions of monoclonal antibodies (MAbs) for oncology indications will not allay […]
August 4, 2011
Developing the Nation’s Biosimilars Program Steven Kozlowski, M.D., Janet Woodcock, M.D., Karen Midthun, M.D., and Rachel Behrman Sherman, M.D., M.P.H. New England Journal of Medicine August 4, 2011 Biologic products developed over the past three decades and approved by the Food and Drug Administration (FDA) now provide important therapeutic options for a variety of serious […]
August 3, 2011
Reuters By Anna Yukhananov Evaluating generic versions of complex biotechnology medicines will require a new, more rigorous review process, U.S. drug regulators said, in the first glimpse of their thinking on the subject. Drugmakers, investors and others have been clamoring for more insight into the approval process for cheaper versions of biotech drugs, known as […]
August 1, 2011
By Helena R. Berger, Executive Vice President & CEO, American Association of People with Disabilities Buffalo News The future of medicine is biologic drugs. Not only have they revolutionized the medical treatments of serious diseases, they have also transformed treatments for many people with disabilities – from offering new promise to people with multiple sclerosis […]
August 1, 2011
By Helena R. Berger, Executive Vice President & CEO, American Association of People with Disabilities Buffalo News The future of medicine is biologic drugs. Not only have they revolutionized the medical treatments of serious diseases, they have also transformed treatments for many people with disabilities – from offering new promise to people with multiple sclerosis […]
July 28, 2011
Orange County Register By Thair Phillips, President, RetireSafe The biotech revolution has brought hope to millions of Americans coping with some of the most devastating medical conditions, including cancer, Parkinson’s disease and rheumatoid arthritis. New prescription drugs, known as biologics, that were born of this revolution now comprise the fastest-growing segment of the pharmaceutical market […]
July 28, 2011
Orange County Register By Thair Phillips, President, RetireSafe The biotech revolution has brought hope to millions of Americans coping with some of the most devastating medical conditions, including cancer, Parkinson’s disease and rheumatoid arthritis. New prescription drugs, known as biologics, that were born of this revolution now comprise the fastest-growing segment of the pharmaceutical market […]
July 11, 2011
By John Horton, President of LegitScript Oregon Statesman Journal In just the first three days of summer, at least six unrelated pharmaceutical manufacturers you’ve probably never heard of — companies with names like Xcellerex, Avesthagen, NeuClone and Lupin — were the subject of various press releases. The content varied, but all of the news involved […]
